Education

Ph.D in Biochemistry, University of Manchester, 1990

Current Position

Senior Research Fellow, School of Medicine, Medical sciences and Nutrition, Biomedical Physics, University of Aberdeenz

Publications

1. Phyu, S. M., Tseng, C. C., Fleming, I. N. and Smith, T. A. D. (2016). Probing the PI3K/Akt/mTor pathway using 31P-NMR spectroscopy: routes to glycogen synthase kinase 3. Scientific Reports 6: article36544
2. Smith, T. A. and Phyu, S. M. (2016). Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells. PLoS One 11(3): e0151179.
3. Smith, T. A., Phyu, S. M. and Akabuogu, E. U. (2016). Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells. Anticancer Res 36(1): 87-93.
4. Cooper, A. C., Fleming, I. N., Phyu, S. M. and Smith, T. A. (2015). Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling. J Cancer Res Clin Oncol 141(9): 1523-1532.
5. Fleming, I. N., Andriu, A. and Smith, T. A. (2014). Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1alpha. Breast Cancer Res Treat 144(2): 241-248.
6. Schweiger, L. F. and Smith, T. A. (2013). Fully-automated radiosynthesis and in vitro uptake investigation of [N-methyl-(1)(1)C]methylene blue. Anticancer Res 33(10): 4267-4270.
7. Smith, T. A., Zanda, M. and Fleming, I. N. (2013). Hypoxia stimulates 18F-fluorodeoxyglucose uptake in breast cancer cells via hypoxia inducible factor-1 and AMP-activated protein kinase. Nucl Med Biol 40(6): 858-864.
8. Trembleau, L., Smith, T. A. and Abdelrahman, M. H. (2013). Receptor conformational change induces fluoride binding despite competitive water binding. Chem Commun (Camb) 49(52): 5850-5852.
9. Smith, T. A., Appleyard, M. V., Sharp, S., Fleming, I. N., Murray, K. and Thompson, A. M. (2013). Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters. Cancer Chemother Pharmacol 71(2): 473-480.
10. Smith, T. A. D. (2012). [18F]Fluoride Labelling of Macromolecules in Aqueous Conditions: Silicon and boroaryl based [18F]fluorine acceptors, [18F]FDG conjugation and Al18F chelation. J Label Compounds & RadioPharmaceut 55: 281-288.
11. Law, A. A., Collie-Duguid, E. S. and Smith, T. A. (2012). Influence of resistance to 5-fluorouracil and tomudex on [18F]FDG incorporation, glucose transport and hexokinase activity. Int J Oncol 41(1): 378-382.
12. Trembleau, L., Simpson, M., Cheyne, R. W., Escofet, I., Appleyard, M. V., Sharp, S., Murray, K., Thompson, A. M. and Smith, T. A. D. (2011). Development of 18F-fluorinatable dendrons and their application to cancer cell targeting. New J Chem 35: 2496-2502.
13. Smith, T. A. and Cheyne, R. W. (2011). Predicting tumour response to anti-HER1 therapy using medical imaging: a literature review and in vitro study of [18F]-FDG incorporation by breast cancer cells responding to cetuximab. Br J Biomed Sci 68(3): 158-166.
14. Smith, T. A., Simpson, M., Cheyne, R. and Trembleau, L. (2011). 18F -PEG-biotin: Precursor (boroaryl-PEG-biotin) synthesis, 18F -labelling and an in-vitro assessment of its binding with Neutravidin-trastuzumab pre-treated cells. Appl Radiat Isot 69(10): 1395-1400.
15. Cheyne, R. W., Smith, T. A., Trembleau, L. and McLaughlin, A. C. (2011). Synthesis and characterisation of biologically compatible TiO2 nanoparticles. Nanoscale Res Lett 6(1): 423.
16. Cheyne, R. W., Trembleau, L., McLaughlin, A. and Smith, T. A. (2011). Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab. Nucl Med Biol 38(3): 339-346.
17. Simpson, M., Trembleau, L., Cheyne, R. W. and Smith, T. A. (2011). One-pot production of 18F-biotin by conjugation with 18F-FDG for pre-targeted imaging: synthesis and radio-labelling of a PEGylated precursor. Appl Radiat Isot 69(2): 418-422.
18. Smith, T. A. (2010). Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging. Br J Radiol 83(992): 638-644.
19. Onega, M., Domarkas, J., Deng, H., Schweiger, L. F., Smith, T. A., Welch, A. E., Plisson, C., Gee, A. D. and O'Hagan, D. (2010). An enzymatic route to 5-deoxy-5-[18F]fluoro-D-ribose, a [18F]-fluorinated sugar for PET imaging. Chem Commun (Camb) 46(1): 139-141.
20. Smith, T. A. (2010). Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer. Nucl Med Biol 37(1): 51-55.